Vertex pharmaceuticals inc(VRTX.US AI Earnings Summary)
VRTX AI Earnings Summary (In-Depth)
2026 Q3
Key Highlights
- Stock Price Reaction: The company released earnings after the U.S. market closed on November 2, 2026. The pre-release regular-session close was $553.15; the first full trading session after the release, November 3, closed at $530.76, down approximately 4.05%. An individual after-hours quote does not represent the next full session, and the price move alone does not establish its cause.
- Market Expectations: Revenue of $3.4408 billion was approximately 0.6% above the pre-release estimate of $3.42 billion; non-GAAP diluted EPS of $4.76 was approximately 0.8% below $4.80, broadly in line.
- Performance vs. Previous Guidance: No quarterly gross-margin guidance was issued. The annual outlook remains slightly below 86%; higher annual expenses incorporate Crinetics costs excluded from the prior guidance.
- In One Sentence: CF switching and new products supported revenue growth, the acquisition established a fourth commercial pillar, and shares closed approximately 4.05% lower in the first full session after earnings.
Quarterly Highlights
Four commercial pillars are advancing, with a potential fifth renal franchise pending approval.
Total revenue increased 12% year-over-year, slightly above market expectations: Total revenue for 2026 Q3 reached 3.44 billion, with the US market growing 10% and international markets growing 16% (CF international up 12%, or 10% on a constant currency basis), where foreign exchange tailwinds contributed approximately 1 percentage point. Non-CF products (CASGEVY, JOURNAVX, PALSONIFY) collectively contributed over 0.167 billion, as the diversification continues to deepen.
CF core business remains solid, ALYFTREK becomes the new standard: Global CF revenue for Q3 reached 3.27 billion, an 8% increase year-over-year. ALYFTREK global sales reached 0.706 billion for the quarter, a massive 186% increase; year-to-date US sales have surpassed 1 billion, with over 18,000 patients globally benefiting and reimbursement secured in 31 countries outside the U.S.
CASGEVY gene therapy scales up, increasing 30% quarter-over-quarter: Q3 revenue for CASGEVY reached 99 million, a 30% increase from the previous quarter, with over 100 patient starts for four consecutive quarters. The number of patients infused in the first nine months of 2026 is already double that of the full year 2025, with more than 750 cumulative patient starts globally; management indicated good visibility into the infusion schedule through year-end and early 2027.
JOURNAVX prescriptions grew over 40% QoQ, becoming the #1 oral pain medication brand in the US: JOURNAVX prescriptions exceeded 750,000 in Q3, a growth of over 40% from the previous quarter. To date, more than 1.6 million US patients have been treated, making it the highest-prescribed branded oral pain medication in the US. Q3 revenue reached 58 million, up 18% QoQ, with managed care coverage now at 82%.
Crinetics acquisition closed, integration progressing, rare endocrine diseases become the fourth commercial pillar: The acquisition of Crinetics Pharmaceuticals closed on September 1, and PALSONIFY officially became VRTX's eighth commercialized drug. PALSONIFY contributed 10 million in revenue for the single month of September and approximately $60 million in year-to-date PALSONIFY product sales, including the pre-acquisition period; Vertex recognized only approximately $10 million in September; US reimbursement coverage is currently around 80%, with brand market share exceeding 40% among new patient starts or switches.
Dense milestones in the renal pipeline, povetacicept launch imminent: The US PDUFA date for povetacicept (pove) in IgA nephropathy (IgAN) is November 30. The renal sales force is fully in place, with over 90% having a nephrology background. The AMPLITUDE Phase 2/3 pivotal trial has completed enrollment of all 522 patients, and AMPLIFIED Phase 2 data showed a 42.7% reduction in UACR in Cohort 1, laying a confident foundation for the interim analysis in early 2027.
Next-gen CF corrector VX-828 shows impressive clinical data, triple-molecule strategy advancing steadily: In a triple-therapy study of only eight patients with F/MF mutations, VX-828 showed a sweat chloride reduction of 6.6 mmol/L on day 28 compared to TRIKAFTA baseline, with a mean reduction through four weeks of 9.4 mmol/L. It is a once-daily oral drug with a good safety and drug-drug interaction (DDI) profile. VRTX will wait for data from VX-581 and VX-272 before selecting the best candidate among the three molecules to advance to pivotal trials.
T1D cell therapy strategy adjusted, VX-017 becomes the lead program: VRTX has designated VX-017 (an allogeneic islet cell therapy suitable for all blood types) as the lead program for type 1 diabetes (T1D), expanding the target patient population from approximately 60,000 to 120,000. Dosing has begun in the Phase 1/2 trial, with management aiming to enter pivotal trials in 2027.